FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207789> ?p ?o ?g. }

• W4387207789 endingPage "S95" @default.
• W4387207789 startingPage "S95" @default.
• W4387207789 abstract "The prospective, 2-armed non-randomized HypoFocal phase II trial investigates the safety and feasibility of focal dose escalated external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) for prostate cancer (PCa) patients based on PSMA-PET and multiparametric MRI. This approach improves tumor coverage and thus putatively treatment effectiveness but leads to larger boost volumes. Here we present toxicity and patient reported quality of life (QoL) results after 2 years follow-up (FU) MATERIALS/METHODS: Patients with intermediate- or high-risk PCa and cN0/cM0 stage were included. Patients in arm A received 60 Gy in 20 fractions to the prostate with an integrated boost of up to 75 Gy. Patients in arm B received one session HDR-BT with 15 Gy to the prostate and a boost of up to 19 Gy, followed by EBRT of 44 Gy in 20 fractions. Boost volumes were defined by PSMA-PET and mpMRI based on validated approaches. Genitourinary (GU) and gastrointestinal (GI) toxicity (CTCAE v5.0) and QoL with IPSS and EORTC questionnaires (QLQ30 and PR25) were assessed.Fifty patients were treated in both arms in two centers (Freiburg and Berlin). Table 1 shows patients characteristics. In arm, A grade 2 GU and GI toxicity rates after 2 years were 8% and 4%. There were no grade 3 GU toxicities. Two patients experienced grade 3 GI toxicities due to multifactorial causes. In Arm B grade 2 GU and GI toxicity rates after 2 years were 17% and 0%. No grade 3 toxicities were observed in arm B. Toxicities were not statistically significantly different between baseline and 2y FU (p>0.055). QoL analysis was performed with patients with available questionnaires at baseline and 2y FU (12-15 in Arm A and 13-15 in Arm B). Only bowel function (p = 0.0005, median 4 vs 25 points) in Arm A and sexual- (p = 0.016, median 25 vs 50 points) and bowel function (p = 0.004, median 0 vs 8 points) and dyspnea (p = 0.031, median 0 vs 0 points) in Arm B decreased significantly after 2 year FU. Other QoL items were not significantly different. Bowel symptoms were significantly worse in Arm A compared to Arm B (p = 0.003). Median PSA values after 2 years were 0.23 ng/ml in Arm A and 0.33 ng/ml in Arm B.Despite large boost volumes, the 2 years FU of the HypoFocal-Phase II trials shows no significantly increased GU and GU toxicities compared to baseline symptoms. Patients reported about a good QoL but increased bowel symptoms after 2 years, particularly if treated with EBRT only. Implementation of PSMA-PET into focal dose escalated radiotherapy approaches appears safe and feasible. However, radioproctitis demands careful management. The current PSA values suggest a highly effective therapy, but longer FU is needed to evaluate oncological outcomes. The HypoFocal-SBRT phase III trial will evaluate the PSMA-PET and mpMRI-based focal dose escalated SBRT." @default.
• W4387207789 created "2023-09-30" @default.
• W4387207789 creator A5007131086 @default.
• W4387207789 creator A5010549062 @default.
• W4387207789 creator A5013713276 @default.
• W4387207789 creator A5017045993 @default.
• W4387207789 creator A5017091430 @default.
• W4387207789 creator A5020162911 @default.
• W4387207789 creator A5026861429 @default.
• W4387207789 creator A5028171849 @default.
• W4387207789 creator A5028333961 @default.
• W4387207789 creator A5030062662 @default.
• W4387207789 creator A5030091453 @default.
• W4387207789 creator A5062867130 @default.
• W4387207789 creator A5062935566 @default.
• W4387207789 creator A5063481984 @default.
• W4387207789 creator A5068030917 @default.
• W4387207789 creator A5073149984 @default.
• W4387207789 creator A5085968028 @default.
• W4387207789 creator A5086100913 @default.
• W4387207789 creator A5089050618 @default.
• W4387207789 date "2023-10-01" @default.
• W4387207789 modified "2023-10-17" @default.
• W4387207789 title "Toxicity and Patient Reported Quality of Life after PSMA-PET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial" @default.
• W4387207789 doi "https://doi.org/10.1016/j.ijrobp.2023.06.427" @default.
• W4387207789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784612" @default.
• W4387207789 hasPublicationYear "2023" @default.
• W4387207789 type Work @default.
• W4387207789 citedByCount "0" @default.
• W4387207789 crossrefType "journal-article" @default.
• W4387207789 hasAuthorship W4387207789A5007131086 @default.
• W4387207789 hasAuthorship W4387207789A5010549062 @default.
• W4387207789 hasAuthorship W4387207789A5013713276 @default.
• W4387207789 hasAuthorship W4387207789A5017045993 @default.
• W4387207789 hasAuthorship W4387207789A5017091430 @default.
• W4387207789 hasAuthorship W4387207789A5020162911 @default.
• W4387207789 hasAuthorship W4387207789A5026861429 @default.
• W4387207789 hasAuthorship W4387207789A5028171849 @default.
• W4387207789 hasAuthorship W4387207789A5028333961 @default.
• W4387207789 hasAuthorship W4387207789A5030062662 @default.
• W4387207789 hasAuthorship W4387207789A5030091453 @default.
• W4387207789 hasAuthorship W4387207789A5062867130 @default.
• W4387207789 hasAuthorship W4387207789A5062935566 @default.
• W4387207789 hasAuthorship W4387207789A5063481984 @default.
• W4387207789 hasAuthorship W4387207789A5068030917 @default.
• W4387207789 hasAuthorship W4387207789A5073149984 @default.
• W4387207789 hasAuthorship W4387207789A5085968028 @default.
• W4387207789 hasAuthorship W4387207789A5086100913 @default.
• W4387207789 hasAuthorship W4387207789A5089050618 @default.
• W4387207789 hasConcept C121608353 @default.
• W4387207789 hasConcept C126322002 @default.
• W4387207789 hasConcept C126838900 @default.
• W4387207789 hasConcept C126894567 @default.
• W4387207789 hasConcept C133507102 @default.
• W4387207789 hasConcept C143998085 @default.
• W4387207789 hasConcept C159110408 @default.
• W4387207789 hasConcept C188816634 @default.
• W4387207789 hasConcept C2775908122 @default.
• W4387207789 hasConcept C2776235491 @default.
• W4387207789 hasConcept C2777416452 @default.
• W4387207789 hasConcept C2779951463 @default.
• W4387207789 hasConcept C2780192828 @default.
• W4387207789 hasConcept C29730261 @default.
• W4387207789 hasConcept C2989005 @default.
• W4387207789 hasConcept C509974204 @default.
• W4387207789 hasConcept C71924100 @default.
• W4387207789 hasConceptScore W4387207789C121608353 @default.
• W4387207789 hasConceptScore W4387207789C126322002 @default.
• W4387207789 hasConceptScore W4387207789C126838900 @default.
• W4387207789 hasConceptScore W4387207789C126894567 @default.
• W4387207789 hasConceptScore W4387207789C133507102 @default.
• W4387207789 hasConceptScore W4387207789C143998085 @default.
• W4387207789 hasConceptScore W4387207789C159110408 @default.
• W4387207789 hasConceptScore W4387207789C188816634 @default.
• W4387207789 hasConceptScore W4387207789C2775908122 @default.
• W4387207789 hasConceptScore W4387207789C2776235491 @default.
• W4387207789 hasConceptScore W4387207789C2777416452 @default.
• W4387207789 hasConceptScore W4387207789C2779951463 @default.
• W4387207789 hasConceptScore W4387207789C2780192828 @default.
• W4387207789 hasConceptScore W4387207789C29730261 @default.
• W4387207789 hasConceptScore W4387207789C2989005 @default.
• W4387207789 hasConceptScore W4387207789C509974204 @default.
• W4387207789 hasConceptScore W4387207789C71924100 @default.
• W4387207789 hasIssue "2" @default.
• W4387207789 hasLocation W43872077891 @default.
• W4387207789 hasLocation W43872077892 @default.
• W4387207789 hasOpenAccess W4387207789 @default.
• W4387207789 hasPrimaryLocation W43872077891 @default.
• W4387207789 hasRelatedWork W1993064858 @default.
• W4387207789 hasRelatedWork W2043597413 @default.
• W4387207789 hasRelatedWork W2055348823 @default.
• W4387207789 hasRelatedWork W2056478550 @default.
• W4387207789 hasRelatedWork W2062703397 @default.
• W4387207789 hasRelatedWork W2152117445 @default.
• W4387207789 hasRelatedWork W2788839829 @default.
• W4387207789 hasRelatedWork W3107045007 @default.
• W4387207789 hasRelatedWork W4206581437 @default.
• W4387207789 hasRelatedWork W56824131 @default.

• next